Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

The Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myocardial injury after CABG are lacking. Previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after CABG, compared to placebo.

Inclusion Criteria:

Patients undergoing CABG without valve surgery

Exclusion Criteria:

• emergency cardiac surgery
• any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization
• patients with cholestatic jaundice (total bilirubin > 2-fold ULN)
• severe liver disease (AST or ALT > 3-fold ULN)